Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer has officially closed on its $10 billion purchase of obesity drug maker Metsera. So what does everyone think of the ...

Just one month into his job, Novo Nordisk’s new chief executive went to bed one night in September thinking he had secured a ...

Investing.com -- Pfizer Inc plans to expand its obesity portfolio globally with a focus on oral medications following its Metsera acquisition, Chief Financial Officer Dave Denton said at the Jefferies ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Here's why these two healthcare stocks scan as no-brainer buys right now.

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

Pfizer Inc. has announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical ...

Paul Sweeney harnesses the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.